China

¡Bienvenido/a! En esta página encontrarás las últimas noticias legales, publicaciones y eventos en China. Para mantenerte al corriente de las últimas novedades, guarda esta página en tu teléfono móvil o regístrate para recibir alertas electrónicas.

CMS es clave en China: para obtener más información, haga clic aquí.

Artículos Recientes

  •  
    04/12/2024
    China

    A New Adventure for Wholly Foreign Invested Hospital

    1. Brief Summary of Development of Wholly Foreign-Invested Hospitals Regulations in the People’s Republic of China (“PRC”)Wholly foreign-invested hospitals have always been a sector under relatively strict regulation in the PRC, except for limited cases as pilots. One of the very first legal documents allowing foreign investors to set up wholly foreign invested hospitals is the Tentative Administrative Measures on Wholly Foreign Invested Medical Institutes of China (Shanghai) Pilot Free Trade Zones issued on 13 November 2013. This regulation focuses on the procedures and conditions...
    Leer más
  •  
    03/12/2024
    China

    Chinese Tax Regulation Update - October & November 2024

    The latest development in China Tax Regulation mainly includes:Key updates to administrative measures for taxation on the imported and exported goodsWater Resource Tax (“WRT”) reformExpansion of the scope of tax refund at the port of departureNationwide rollout of fully digitalized e-invoicesAdjustments of export tax refund policiesPlease click here to read the full article.
    Leer más
  •  
    02/12/2024
    China

    China Overhauls its Rules of Foreign Strategic Investment in A-share Listed Companies

    On 1 November 2024, the long-awaited Administrative Measures for Strategic Investments in Listed Companies by Foreign Investors (“New Measures”) were jointly released by six government departments, including the Ministry of Commerce (“MOFCOM”) and the Securities Regulatory Commission. The New Measures have taken effect on 2 December 2024. They introduce significant changes, in particular in the areas of eligibility of foreign investors, investment modes, shareholding ratio threshold, lock-up period, and other obligations of the parties concerned.Currently, valuations in...
    Leer más
  •  
    28/11/2024
    International

    CMS’s insights on COP29 themes

    The discussions at COP29 Azerbaijan show how difficult it is to achieve global environmental goals. CMS lawyers have been reflecting on the themes of the conference in short videos and articles, housed on the CMS COP29 hub.A summary of CMS’s coverage is below and if you’d like to hear directly from the CMS COP29 delegates, now home from Baku, please join their discussion on Friday 29 November by registering here: CMS at COP29 online sessionBridgett Majola reflects on the need to align climate finance contributions with global needs and the current situation in Africa.Munir Hassan discusses...
    Leer más
  •  
    25/11/2024
    International

    Pre-hedging: IOSCO publishes delayed Consultation Report

    On 21 November 2024, the International Organization of Securities Commissions (“IOSCO”) published a consultation paper in response to concerns about the appropriateness of pre-hedging practices raised by various market participants, standard setters and national and supra-national authorities. In short, pre-hedging is the well-established practice by which dealers in certain markets look to hedge their exposure to anticipated client orders for a number of reasons, including to enable the dealer to take on the risk of the client order once confirmed, and to offer a competitive price.BackgroundEuropean...
    Leer más
  •  
    20/11/2024
    China

    China’s NMPA issues more detailed requirements for overseas drug MAHs and their domestic responsible persons

    On 13 November 2024, the National Medical Products Administration (NMPA) formally promulgated the Interim Provisions on the Administration of the Designation of Domestic Responsible Persons by Overseas Drug Marketing Authorisation Holders. These Interim Provisions further clarify the requirements and related obligations for overseas drug Marketing Authorisation Holders (MAHs) when selecting their domestic responsible persons (DRPs).In recent years, China has strengthened regulatory supervision in the life sciences sector. A key part of China's regulatory framework, the DRP system ensures the quality...
    Leer más